Amylyx Pharmaceuticals (AMLX) Enterprise Value (2021 - 2025)
Historic Enterprise Value for Amylyx Pharmaceuticals (AMLX) over the last 5 years, with Q3 2025 value amounting to -$344.0 million.
- Amylyx Pharmaceuticals' Enterprise Value fell 4675.65% to -$344.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$344.0 million, marking a year-over-year decrease of 4675.65%. This contributed to the annual value of -$176.5 million for FY2024, which is 5247.2% up from last year.
- Latest data reveals that Amylyx Pharmaceuticals reported Enterprise Value of -$344.0 million as of Q3 2025, which was down 4675.65% from -$180.8 million recorded in Q2 2025.
- In the past 5 years, Amylyx Pharmaceuticals' Enterprise Value ranged from a high of -$96.1 million in Q4 2021 and a low of -$373.3 million during Q1 2024
- In the last 5 years, Amylyx Pharmaceuticals' Enterprise Value had a median value of -$282.5 million in 2022 and averaged -$270.0 million.
- In the last 5 years, Amylyx Pharmaceuticals' Enterprise Value crashed by 26095.74% in 2022 and then skyrocketed by 5247.2% in 2024.
- Quarter analysis of 5 years shows Amylyx Pharmaceuticals' Enterprise Value stood at -$96.1 million in 2021, then plummeted by 260.96% to -$346.9 million in 2022, then decreased by 7.04% to -$371.4 million in 2023, then soared by 52.47% to -$176.5 million in 2024, then crashed by 94.89% to -$344.0 million in 2025.
- Its Enterprise Value was -$344.0 million in Q3 2025, compared to -$180.8 million in Q2 2025 and -$204.1 million in Q1 2025.